Head and neck cancer

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

immune checkpoint inhibition

nivolumab
Checkmate-141, 2016      NCTnivolumabstandard treatment2L 2nd line platinum failure Risk of bias conclusive
pembrolizumab
KEYNOTE-040    NCTpembrolizumabstandard treatment2L 2nd line Risk of bias negative

Induction chemotherapy

not classified
Richard (IGR-65), 1974   CT with methotrexateno induction chemotherapynegative
Fazekas (RTOG 6801), 1980   CT with methotrexateno induction chemotherapynegative
Toohill (MCW-2), 1987   PFno induction chemotherapynegative
Lewin (SHNG-85), 1997   PFno induction chemotherapynegative
Paccagnella (GSTTC-86 ), 1994     PFno induction chemotherapynegative
Domenge (GETTEC neo1), 1995     PFno induction chemotherapynegative
Domenge (GETTEC), 2000     PFno induction chemotherapynegative
Dalley (AHNTG), 1995   PFno induction chemotherapynegative
Tejedor (Las Palmas), 1992   PFno induction chemotherapynegative
Gedouin (Rennes-87), 1996   PFno induction chemotherapynegative
Di Blasio (Parma), 1994   PFno induction chemotherapynegative
Depondt (CFHNS), 1993   PFno induction chemotherapynegative
Volling (Cologne), 1994     PFno induction chemotherapynegative
Hasegawa (HNAP-02), 1996   PFno induction chemotherapy -
BNH 003     PFno induction chemotherapynegative
RTOG 91-11 (I+RT vs RT alone), 2003     PFno induction chemotherapysuggesting
Hareyama, 2002     PFno induction chemotherapy -
Licitra, 2003      NCTPFno induction chemotherapynegative
EORTC 24844     PFno induction chemotherapynegative
HNCP, 1987     polyCT with platinno induction chemotherapynegative
Schuller (SWOG 8006), 1988   polyCT with platinno induction chemotherapynegative
Szpirglas (Pitié-81 ), 1988   polyCT with platinno induction chemotherapynegative
Carugati (Buenos Aires ), 1988   polyCT with platinno induction chemotherapynegative
Mazeron (Créteil-82), 1992     polyCT with platinno induction chemotherapynegative
Brunin (HNCGIC02), 1989   polyCT with platinno induction chemotherapynegative
Salvajoli (AC Camargo), 1992   polyCT with platinno induction chemotherapynegative
Jaulerry Trial 2 (Curie)(HNCGIC03), 1992     polyCT with platinno induction chemotherapynegative
Maipang (Songkla), 1995   polyCT with platinno induction chemotherapynegative
Kohno, 2000     polyCT with platinno induction chemotherapynegative
Jortay (EORTC 24771), 1990   polyCT without platinno induction chemotherapynegative
Richard (EORTC 78-OCP), 1991   polyCT without platinno induction chemotherapynegative
Holoye (MCW-1), 1985     polyCT without platinno induction chemotherapynegative
Chauvergne, 1988   polyCT with platincisplatinnegative
De Andres, 1995   carboplatin, 5FUPFnegative
Clark (Dana farber cancer Institute 83-084), 1988     PBMPFnegative
Fonseca, 2005     TPPFnegative
EORTC 24971 (TAX 323), 2006        NCTTPFPFsuggesting
Posner (TAX324), 2007      NCTTPFPFsuggesting
GORTEC 2000-01      NCTTPFPFsuggesting
TAX324 (Larynx preservation subset), 2007    NCTTPFPF -
Prévost, 2005     VP16 based CTPFnegative
Fonseca, 1997     PF with leucovorinPF without leucovorinnegative
GETTEC, 1998     induction PFsurgerysuggesting
Veterans Affairs, 1998     induction PFsurgerysuggesting
EORTC 24891, 1996       induction PFsurgerysuggesting
paclitaxel
Hitt paclitaxel, 2005     paclitaxel based CTPFsuggesting